Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zilovertamab vedotin by Merck for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to...
Zilovertamab vedotin by Merck for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Zilovertamab vedotin by Merck for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
Zilovertamab vedotin by Merck for Non-Hodgkin Lymphoma: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Lymphoma: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase I for Lymphoma. According to GlobalData, Phase I...
Zilovertamab vedotin by Merck for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
Zilovertamab vedotin by Merck for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According...
Zilovertamab vedotin by Merck for Follicular Lymphoma: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Mantle Cell Lymphoma: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
Zilovertamab vedotin by Merck for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According...
Zilovertamab vedotin by Merck for Ureter Cancer: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Ureter Cancer. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Urethral Cancer: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Urethral Cancer. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Bladder Cancer: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Bladder Cancer. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Zilovertamab vedotin by Merck for Pancreatic Cancer: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Ovarian Cancer: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Gastric Cancer: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Merck's Zilovertamab vedotin?
Zilovertamab vedotin is a monoclonal antibody conjugated commercialized by Merck, with a leading Phase III program in Diffuse Large B-Cell...